RecruitingPhase 2NCT06160791

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jerry Lee, MD, MSc, MPhil
Principal Investigator
Jerry Lee, MD
University of California, San Francisco
Intervention
Ruxolitinib(drug)
Enrollment
36 enrolled
Eligibility
18 years · All sexes
Timeline
20242029

Study locations (2)

Collaborators

Incyte Corporation · UC Hematological Malignancies Consortium (UCHMC)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06160791 on ClinicalTrials.gov

Other trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Additional recruiting or active studies for the same condition.

See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

← Back to all trials